

CLAIMS

1. A method of treating BPH in a subject in need of such treatment which method comprises administering to said subject an effective amount of a  
5 combination of (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) an  $\alpha_1$ -adrenergic receptor antagonist, or a pharmaceutically acceptable derivative thereof.
2. ~~2.~~ The method of claim 1 wherein (A) and (B) are administered  
10 simultaneously, sequentially or separately.
3. ~~3.~~ The method of claim 1, wherein (B) is selected from terazosin, doxazosin, prazosin, bunazosin, alfuzosin, naftopidil, tamsulosin, silodosin, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a pharmaceutically acceptable derivative thereof.
4. ~~4.~~ The method of claim 4, wherein (B) is doxazosin or a pharmaceutically acceptable derivative thereof.
5. ~~5.~~ The method of claim 4, wherein (B) is 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.  
25
6. ~~6.~~ The method of claim 4, wherein (B) is 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone, or a pharmaceutically acceptable derivative thereof.
7. ~~7.~~ A pharmaceutical composition comprising (A) atorvastatin, or a pharmaceutically acceptable derivative thereof, and (B) doxazosin, or a pharmaceutically acceptable derivative thereof.  
30

Rule  
1.12b

8. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.

5

9. 10. A pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof.

10

10. 11. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) doxazosin or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.

15

11. 12. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof, 20 for simultaneous, sequential or separate administration in the treatment of BPH.

12. 13. A pharmaceutical composition comprising, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1,6]-naphthyridin-25 6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.

13. 14. A pharmaceutical composition according to any one of claims 8 to 13, 30 further comprising a pharmaceutically acceptable carrier.